Affordable Access

Access to the full text

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Authors
  • Vanderstichele, Hugo Marcel1
  • Teunissen, Charlotte E.2
  • Vanmechelen, Eugeen3
  • 1 Biomarkable, Ghent, Belgium , Ghent (Belgium)
  • 2 Amsterdam University Center, Amsterdam, The Netherlands , Amsterdam (Netherlands)
  • 3 Key4AD, Eke, Belgium , Eke (Belgium)
Type
Published Article
Journal
Neurology and Therapy
Publisher
Springer Healthcare
Publication Date
Dec 12, 2019
Volume
8
Issue
Suppl 2
Pages
129–145
Identifiers
DOI: 10.1007/s40120-019-00166-3
Source
Springer Nature
Keywords
License
Yellow

Abstract

This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).

Report this publication

Statistics

Seen <100 times